Cyclofenil

Summary

Cyclofenil (CHEMBL141305) is an approved small molecule (ATC G03GB01).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G03GB01
• Chemistry: 364.4 Da · C23H24O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL141305
Name	Cyclofenil
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2898
ATC	G03GB01
Molecular formula	C23H24O4
Molecular weight	364.4
InChIKey	GVOUFPWUYJWQSK-UHFFFAOYSA-N

SMILES: CC(=O)OC1=CC=C(C=C1)C(=C2CCCCC2)C3=CC=C(C=C3)OC(=O)C

IUPAC name: [4-[(4-acetyloxyphenyl)-cyclohexylidenemethyl]phenyl] acetate

Also known as: Ciclofenilo, Cyclofenil, F 6066, F-6066, ICI 48213, ICI-48213, Neoclym, NSC-86464, Rehibin, Sexovid, SID29217524, cyclofenil

Patent coverage: 404 distinct patent families (1,320 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Ferritin light chain, Androgen receptor, Estrogen receptor, Progesterone receptor, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Sodium-dependent dopamine transporter, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ESR1	7.58	EC50	26	nM	CHEMBL_ACT_19211890
ESR1	7.57	IC50	27	nM	CHEMBL_ACT_19211883
SLC6A3	6.82	AC50	150	nM	CHEMBL_ACT_25125081
ESR1	6.6	AC50	250	nM	CHEMBL_ACT_25138980
PGR	5.88	AC50	1320	nM	CHEMBL_ACT_25204413
AR	5.79	AC50	1630	nM	CHEMBL_ACT_25203480
ADORA3	5.61	AC50	2470	nM	CHEMBL_ACT_25198821
CHRM2	5.5	AC50	3200	nM	CHEMBL_ACT_25195858
SLC6A2	5	AC50	9970	nM	CHEMBL_ACT_25146122

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).